These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 25446819)

  • 21. Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
    Gurwith M; Condit RC; Excler JL; Robertson JS; Kim D; Fast PE; Drew S; Wood D; Klug B; Whelan M; Mallett Moore T; Khuri-Bulos N; Smith ER; Chen RT; Kochhar S;
    Vaccine; 2020 Nov; 38(49):7702-7707. PubMed ID: 33070999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.
    van Der Most RG; Murali-Krishna K; Ahmed R; Strauss JH
    J Virol; 2000 Sep; 74(17):8094-101. PubMed ID: 10933719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines.
    Condit RC; Kim D; Robertson JS; Excler JL; Gurwith M; Monath TP; Pavlakis G; Fast PE; Smith J; Smith ER; Chen RT; Kochhar S;
    Vaccine; 2020 Nov; 38(49):7708-7715. PubMed ID: 32907759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A live, attenuated recombinant West Nile virus vaccine.
    Monath TP; Liu J; Kanesa-Thasan N; Myers GA; Nichols R; Deary A; McCarthy K; Johnson C; Ermak T; Shin S; Arroyo J; Guirakhoo F; Kennedy JS; Ennis FA; Green S; Bedford P
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6694-9. PubMed ID: 16617103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
    Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
    Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
    Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
    mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
    Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
    Tsetsarkin KA; Maximova OA; Liu G; Kenney H; Teterina NL; Pletnev AG
    mBio; 2019 Apr; 10(2):. PubMed ID: 31015334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Appaiahgari MB; Vrati S
    Expert Rev Vaccines; 2010 Dec; 9(12):1371-84. PubMed ID: 21105774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).
    Chen RT; Carbery B; Mac L; Berns KI; Chapman L; Condit RC; Excler JL; Gurwith M; Hendry M; Khan AS; Khuri-Bulos N; Klug B; Robertson JS; Seligman SJ; Sheets R; Williamson AL;
    Vaccine; 2015 Jan; 33(1):73-5. PubMed ID: 25305565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The yellow fever 17D vaccine virus as a vector for the expression of foreign proteins: development of new live flavivirus vaccines.
    Bonaldo MC; Caufour PS; Freire MS; Galler R
    Mem Inst Oswaldo Cruz; 2000; 95 Suppl 1():215-23. PubMed ID: 11142718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.
    Caufour PS; Motta MC; Yamamura AM; Vazquez S; Ferreira II; Jabor AV; Bonaldo MC; Freire MS; Galler R
    Virus Res; 2001 Nov; 79(1-2):1-14. PubMed ID: 11551641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.
    Grifoni A; Voic H; Dhanda SK; Kidd CK; Brien JD; Buus S; Stryhn A; Durbin AP; Whitehead S; Diehl SA; De Silva AD; Balmaseda A; Harris E; Weiskopf D; Sette A
    J Virol; 2020 May; 94(10):. PubMed ID: 32132233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes.
    Bonaldo MC; Mello SM; Trindade GF; Rangel AA; Duarte AS; Oliveira PJ; Freire MS; Kubelka CF; Galler R
    Virol J; 2007 Oct; 4():115. PubMed ID: 17971212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.